407 related articles for article (PubMed ID: 2963622)
1. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
[TBL] [Abstract][Full Text] [Related]
2. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
[TBL] [Abstract][Full Text] [Related]
6. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
[TBL] [Abstract][Full Text] [Related]
7. The anticoagulant effect of heparan sulfate and dermatan sulfate.
Teien AN; Abildgaard U; Höök M
Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
[No Abstract] [Full Text] [Related]
8. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
[TBL] [Abstract][Full Text] [Related]
9. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo.
Van Ryn-McKenna J; Ofosu FA; Gray E; Hirsh J; Buchanan MR
Ann N Y Acad Sci; 1989; 556():304-12. PubMed ID: 2735661
[TBL] [Abstract][Full Text] [Related]
10. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
Scully MF; Ellis V; Seno N; Kakkar VV
Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
[TBL] [Abstract][Full Text] [Related]
11. The haemorrhagic and antithrombotic effects of dermatan sulphate.
Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
Buchanan MR; Brister SJ
Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
[TBL] [Abstract][Full Text] [Related]
13. Activation of heparin cofactor II by dermatan sulfate.
Tollefsen DM; Pestka CA; Monafo WJ
J Biol Chem; 1983 Jun; 258(11):6713-6. PubMed ID: 6687888
[TBL] [Abstract][Full Text] [Related]
14. The effects of glycosaminoglycans on coagulation: a thromboelastographic study.
Senzolo M; Coppell J; Cholongitas E; Riddell A; Triantos CK; Perry D; Burroughs AK
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):227-36. PubMed ID: 17413758
[TBL] [Abstract][Full Text] [Related]
15. Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans.
Toida T; Maruyama T; Ogita Y; Suzuki A; Toyoda H; Imanari T; Linhardt RJ
Int J Biol Macromol; 1999 Dec; 26(4):233-41. PubMed ID: 10569284
[TBL] [Abstract][Full Text] [Related]
16. Effects of glycosaminoglycans on U-937 leukemia cell proliferation and differentiation: structure-function relationship.
Volpi N; Petrini M; Conte A; Valentini P; Venturelli T; Bolognani L; Ronca G
Exp Cell Res; 1994 Nov; 215(1):119-30. PubMed ID: 7957660
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the activity of a heparan sulphate of defined molecular weight range (7500-15,000 Da) with heparin and dermatan sulphate.
Gervasi GB; Catalani R; Bartoli C; Carpita G; Farina C; Gelso E
Pharmacol Res; 1995 Jun; 31(6):331-6. PubMed ID: 8685069
[TBL] [Abstract][Full Text] [Related]
19. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
Fernandez FA; Buchanan MR; Hirsh J; Fenton JW; Ofosu FA
Thromb Haemost; 1987 Jun; 57(3):286-93. PubMed ID: 3116701
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant properties in vitro of heparan sulphates.
Hubbard AR; Jennings CA; Barrowcliffe TW
Thromb Res; 1984 Sep; 35(5):567-76. PubMed ID: 6237461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
